A graduate of the University of Melbourne, Dr Sikaris trained at the Royal Melbourne, Queen Victoria, and Prince Henry’s Heidelberg Repatriation Hospitals. He obtained fellowships from the Royal College of Pathologists of Australasia and the Australasian Association of Clinical Biochemists in 1992 and 1997 respectively.
Dr Sikaris was Director of Chemical Pathology at St Vincent’s Hospital in Melbourne between 1993 and 1996. A NATA-accredited laboratory assessor, Dr Sikaris specialises in Prostate Specific Antigen, cholesterol and quality assurance and is currently chair of the International Federation of Clinical Chemistry Committee on Analytical Quality. His expertise is highly sought and he has presented extensively at national and international symposiums.
Notes
Papers Referenced
The Clinical Biochemistry of Obesity
The Clinical Biochemistry of Obesity—More Than Skin Deep
The nutritional geometry of liver disease including non-alcoholic fatty liver disease
Soft Drink Consumption Linked with Fatty Liver in the Absence of Traditional Risk Factors
The mystery of evacetrapib - why are CETP inhibitors failing?
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
LDL cholesterol: controversies and future therapeutic directions
Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial
Notes:
Once damaged (oxidate/glycated) LDL is absorbed by macrophages and not the liver.
- Anybody who is thinking cholesterol is bad 30 years out of date.
- Anybody who is thinking LDL is bad is bad 20 years out of date.
- Anybody who is saying sdLDL is bad is at least 10 years up to date.
- Anybody who is questioning what makes sdLDL so atherogenic is up to date.
- lbLDL (large buoyant ) - is good and can be seen in a density analysis
- sdLDL (small dense) - is atherogenic
lipid energy hypothesis is about energy, not atherogenesis